TB-500

TB-500 is a synthetic peptide fragment corresponding to the active region of thymosin beta-4 (Tb4), a naturally occurring 43-amino-acid protein involved in tissue repair and regeneration.

Profile · 01

Overview

TB-500 is a synthetic peptide fragment corresponding to the active region of thymosin beta-4 (Tb4), a naturally occurring 43-amino-acid protein involved in tissue repair and regeneration. It is not FDA-approved for any human indication and is banned by WADA for athletic use. Preclinical and veterinary studies demonstrate accelerated wound healing, angiogenesis, and anti-inflammatory activity, though human clinical data remain extremely limited. This protocol presents a once-daily subcutaneous approach using practical dilution for clear insulin-syringe measurements.

At a Glance

Goal
Support tissue repair, wound healing, and angiogenesis through the active thymosin beta-4 fragment mechanism
Categories
Tissue RepairWound HealingAnti-InflammatoryRecovery
Synergistic
BPC-157 · GHK-Cu · Collagen Peptides
Profile · 02

Protocol

Suggested daily titration approach starting at 500 mcg and increasing every two weeks.

Typical daily range
500–1000 mcg once daily (gradual titration)
Start
500 mcg daily; increase by ~100–150 mcg every 2 weeks as tolerated
Target
750–1000 mcg daily by Weeks 5–12
Frequency
Once per day (subcutaneous)
Cycle Length
8–12 weeks; optional extension to 16 weeks
Timing
Any consistent time daily; rotate injection sites systematically
Route
Subcutaneous
Cycle
8–12 weeks on, 4 weeks off

Inject once daily subcutaneously using the largest practical dilution to maintain measurement accuracy. Total weekly dose averages ~5 mg, consistent with research protocols. Human clinical validation remains limited; dosing extrapolates from preclinical and veterinary models.

Dose progression

Weeks 1–2
500 mcg (0.5 mg)
Weeks 3–4
600 mcg (0.6 mg)
Weeks 5–8
750 mcg (0.75 mg)
Weeks 9–12
1000 mcg (1.0 mg)

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Science · 01

How TB-500 works.

TB-500 represents the N-terminal active fragment of thymosin beta-4, specifically the heptapeptide sequence Ac-LKKTETQ. This region is responsible for the actin-binding and cell-migration properties of the full thymosin molecule. Preclinical studies demonstrate that TB-500 promotes angiogenesis, accelerates wound healing, and supports tissue regeneration by upregulating cell motility and blood vessel formation. Animal models show enhanced collagen deposition and reduced healing time in injury sites. TB-500 may act as a prodrug, cleaving to an active pentapeptide metabolite. No large-scale controlled human efficacy trials have been completed; current evidence derives primarily from animal injury models and veterinary applications.

Science · 02

Effects

Observations from clinical or preclinical literature.

Supports accelerated wound healing and tissue repair through enhanced angiogenesis and cell migration (animal data)
May reduce inflammation and fibrosis indirectly via thymosin pathways in animal models
Generally well tolerated in veterinary studies with a favorable safety profile
Occasional mild injection-site reactions (redness, tenderness) reported
Human safety data is limited; no large-scale clinical trials have been completed for TB-500 specifically
Long-term human safety and efficacy remain under investigation
Science · 03

Caution

Individuals with active cancer or a history of cancer should avoid use due to TB-500's pro-angiogenic properties
Not recommended during pregnancy or breastfeeding (no safety data available)
TB-500 is banned by WADA for athletic use and is not FDA-approved for human administration
Consult a healthcare provider before use if you have any chronic medical conditions

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Lifestyle · 01

CoFactors

Zinc
Supports wound healing and immune function; commonly depleted in tissue injury.
Vitamin C
Essential cofactor for collagen synthesis and tissue repair.
Magnesium
Supports enzymatic processes involved in tissue recovery.
Omega-3 fatty acids
Support anti-inflammatory pathways complementary to TB-500's mechanisms.
Lifestyle · 02

Life Factors

Complementary strategies for best outcomes.

Maintain adequate protein intake to support tissue repair and regeneration
Combine with appropriate physical activity; avoid overtraining during injury recovery
Prioritize sleep (7–9 hours) to maximize natural recovery and repair
Manage stress levels through evidence-based practices to support overall healing
Lifestyle · 03

Metrics

Day-to-day metrics worth tracking through the protocol.

  1. Pain levels and functional mobility — monitor changes in the target area to gauge healing response
  2. Inflammation markers (subjective swelling, redness, heat) — track daily to identify trends
  3. Sleep quality and recovery perception — poor sleep impairs healing; track to ensure adequate rest
  4. Injection-site reactions — note any redness, swelling, or discomfort to guide site rotation
Lifestyle · 04

Labs

Baseline and periodic bloodwork to monitor systemic health during the protocol.

CRP (C-Reactive Protein)
General inflammation marker; track before and during protocol.
ESR (Erythrocyte Sedimentation Rate)
Secondary inflammation marker to corroborate CRP trends.
CBC (Complete Blood Count)
Monitor overall health and rule out underlying conditions.
CMP (Comprehensive Metabolic Panel)
Assess liver and kidney function during peptide use.
Calculators · 01

Supplies Calculator

Estimates assume the schedule defined for this peptide.

Length
Vial size
Bac. water
Syringe
Vials
0 × 10 mg each…
Syringes
0
Bac. water
0 mL
Swabs
02 per syringe
Calculators · 02

Dose Calculator

Dose Calculator

Vial
Bac. water
Syringe
Dose
Concentration
0mcg/mL
Volume per dose
0mL
…
Practice · 01

Preparation

Careful technique preserves potency. Solution should be clear — do not shake.

  1. Allow vial to reach room temperature for 15–20 minutes before reconstitution.
  2. Draw the chosen bacteriostatic water volume with a sterile syringe.
  3. Inject slowly down vial wall; avoid foaming.
  4. Gently swirl/roll until dissolved (do not shake).
  5. Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
  6. Use within 30 days; discard any unused solution after 30 days.
Practice · 02

Technique

General subcutaneous guidance from clinical best-practice resources.

Clean vial stopper and skin with alcohol; allow to air dry completely
Pinch a skinfold; insert needle at 45–90° into subcutaneous tissue
Do not aspirate for subcutaneous injections; inject slowly and steadily
Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy
Wait 5–10 seconds after injection before withdrawing needle
Discard used syringes immediately in sharps container per WHO guidelines

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Practice · 03

Storage

Lyophilized
Store at room temp in dry, dark conditions; minimize moisture exposure.
Reconstituted
Refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles. Discard reconstituted vials after 30 days.

Notes

Allow vials to reach room temperature before opening to reduce condensation uptake.
Reference · 01

Notes

Use new sterile insulin syringes for each injection; dispose in sharps container
Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation and lipohypertrophy
Inject slowly; wait a few seconds before withdrawing the needle to prevent backflow
Document daily dose, injection site, and observations to maintain consistency
TB-500 is banned by WADA for athletic use and is not FDA-approved for human administration; clinical decisions should involve qualified healthcare providers
Reference · 02

References

  1. FASEB Journal
    Goldstein AL et al., "Thymosin beta-4: actin-sequestering protein active peptide sequences and wound healing".
    https://faseb.onlinelibrary.wiley.com/
  2. Journal of Chromatography A
    Thomas A et al., "TB-500 doping control analysis and detection methods".
    https://www.sciencedirect.com/journal/journal-of-chromatography-a
  3. WADA Scientific Research
    "TB-500 metabolism and detection in anti-doping testing".
    https://www.wada-ama.org/
  4. Racing Medication & Testing Consortium
    "TB-500 in equine sports medicine: veterinary applications".
    https://rmtcnet.com/
  5. Journal of Investigative Dermatology
    Philp D et al., "Thymosin beta-4 promotes wound healing and tissue repair models".
    https://www.jidonline.org/
  6. CenterWatch Clinical Trials
    "Thymosin beta-4 clinical trial listings and status updates".
    https://www.centerwatch.com/
  7. WHO (NCBI Bookshelf)
    "Guideline on safety-engineered syringes for IM, ID, and SC injections in health care settings (2016)".
    https://www.ncbi.nlm.nih.gov/books/NBK390474/
  8. Johns Hopkins Arthritis Center
    "How to give a subcutaneous injection (patient education resource)".
    https://www.hopkinsarthritis.org/patient-corner/how-to-give-a-subcutaneous-injection/
  9. Nursing Journal (LWW)
    "Best practices for subcutaneous injection technique".
    https://journals.lww.com/nursing/
  10. University of Michigan Health
    "Subcutaneous injection patient education and technique guidance".
    https://www.uofmhealth.org/
  11. CDC
    "Vaccine administration: subcutaneous route (angle/site; no aspiration)".
    https://www.cdc.gov/vaccines/hcp/admin/downloads/YCTS-VaxAdmin-Subcut-injection.pdf
  12. Subcutaneous Drug Injection Review (PMC)
    "Pharmacologic considerations of the subcutaneous route".
    https://pmc.ncbi.nlm.nih.gov/articles/PMC6822791/
On this page